Chantal F Stockem,Alberto Gil-Jimenez,Hamza Ali et al. Chantal F Stockem et al.

Purpose: In NABUCCO, safety and efficacy of preoperative ipilimumab plus nivolumab were assessed in stage III urothelial cancer. Encouraging responses were achieved and ipilimumab 3 mg/kg (ipilimumab-high) appeared more effective than ipilimumab 1 mg/kg (ipilimumab-low)....We explored ipilimumab plus nivolumab response biomarkers and tumor micro environment (TME) treatment dynamics....Results: High tumor mutational burden (TMB) and PD-L1 positivity were associated with response to ipilimumab plus nivolumab. Non-responding patients exhibited increased expression of a TGFβ signature....Conclusions: Our data indicate that TMB, PD-L1 and TGFβ are potential biomarkers for response to ipilimumab plus nivolumab in stage III urothelial cancer. An inflammatory TME might be relevant for responding to ipilimumab-low.

Jung Sun Kim,Youngun Kim,Beodeul Kang et al. Jung Sun Kim et al.

Here, we investigate the organ-specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, considering prior ICI exposure, compared with nivolumab (Nivo) monotherapy.

Victorio Cervera,Fabricio Ruiz Victorio Cervera

Methods: We performed a cost-effectiveness analysis comparing nivolumab plus ipilimumab (intervention) with pembrolizumab plus axitinib (comparator) in intermediate and poor-risk aRCC using a 3-state Markov model. We included deterministic and probabilistic sensitivity analyses....Results: In the cost-effectiveness analysis base case, nivolumab plus ipilimumab option generated a mean cost savings per treated patient of -$41,864 and a gain of 0.60 and 0.56 in LYs and QALYs, respectively, with an incremental cost-effectiveness ratio of -$74,266.0....After probabilistic sensitivity analysis, the treatment regimen of nivolumab plus ipilimumab showed a 0.88 probability of being dominant compared with pembrolizumab plus axitinib for the treatment of patients with advanced RCC intermediate-poor risk group....Conclusions: Nivolumab plus ipilimumab represents a cost-saving option for first-line aRCC treatment and a cost-effective regimen for patients with intermediate and poor-risk aRCC in Uruguay.

I M Chen,S Theile,K Madsen et al. I M Chen et al.

Background: Considering strong T-cell response from influenza vaccination, we aimed to evaluate ipilimumab, nivolumab, seasonal influenza vaccine, and stereotactic body radiotherapy (SBRT) treatment efficacy in heavily pr...

Liselotte Tas,Marie B Weitemeyer,Maartje W Rohaan et al. Liselotte Tas et al.

Background: The aim of this study was to describe the impact of surgical resections on tumour-infiltrating lymphocyte (TIL) therapy, based on results from a randomized phase III trial comparing TIL therapy with standard ipilimumab in patients with metastatic melanoma (NCT02278887).

Solange Peters,Meredith M Regan,Luis G Paz-Ares et al. Solange Peters et al.

In CheckMate 227 Part 1, nivolumab plus ipilimumab showed long-term durable overall survival (OS) benefit versus chemotherapy in patients with metastatic NSCLC. Here, we report updated long-term TFS results.

Na Zhou,Mingying Wu,Chenyu Wang et al. Na Zhou et al.

Dual immunotherapy with nivolumab and ipilimumab was given for 3 cycles and only achieved stable disease. Steven-Johnson syndrome occurred afterward and was relieved after steroid treatment.

Lucas Blanchard,Estefania Vina,Jerko Ljubetic et al. Lucas Blanchard et al.

Unexpectedly, we find that the human anti-CTLA-4 antibody ipilimumab fails to increase TA-HEVs in a humanized mouse model.

Caroline Robert,Michal Kicinski,Caroline Dutriaux et al. Caroline Robert et al.

Those in the induction group received targeted therapy (oral encorafenib 450 mg once a day plus oral binimetinib 45 mg twice a day for 12 weeks) followed by immune checkpoint inhibitors (intravenous nivolumab 3 mg/kg plus intravenous ipilimumab 1 mg/kg once every 3 weeks for four doses, followed by intravenous

Anna Olsson-Brown,Ankit Jain,Ricky Frazer et al. Anna Olsson-Brown et al.

This study aimed to generate real-world evidence on irAE characteristics, clinical management and clinical outcomes among patients with advanced (unresectable or metastatic) malignant melanoma (a/mMM) or advanced renal cell carcinoma (aRCC) treated with nivolumab (NIVO) and/or ipilimumab (IPI) in the